Skip to content
Screener

Alumis Inc. ALMS Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.72B-30.8%
Amgen logo
AmgenAMGN
$574M+5.9%
Immunome logo
ImmunomeIMNM
$582.69M+126%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$49.52M-40.7%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$85.61M+101%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$360.25M+65.4%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
(in thousands, except share and per share amounts)March 31, 2026December 31, 2025
Assets
Current assets:
Cash and cash equivalents$63,885$89,670
Restricted cash8682
Marketable securities, current459,058218,831
Research and development prepaid expenses3,3452,909
Other prepaid expenses and current assets6,0336,740
Total current assets532,407318,232

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s cash & equivalents?
Alumis Inc. (ALMS) reported cash & equivalents of $63.89M in Q1 2026.
How has Alumis Inc.'s cash & equivalents changed year-over-year?
Alumis Inc.'s cash & equivalents decreased by 50.3% year-over-year, from $128.54M to $63.89M.
What is the long-term trend for Alumis Inc.'s cash & equivalents?
Over 2 years (2023 to 2025), Alumis Inc.'s cash & equivalents has grown at a 39.6% compound annual growth rate (CAGR), from $46M to $89.67M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Alumis Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude